資金動向 | 北水淨買入港股逾52億港元,連續14日加倉建設銀行
南下資金今日淨買入港股52.2億港元。
其中:淨買入建設銀行9.57億、中芯國際7.14億、美團-W 3.77億、快手-W 3.14億、信達生物3.13億;淨賣出阿里巴巴-W 5.51億、中國銀行3.8億、騰訊控股3.25億、泡泡瑪特1.57億、小米集團-W 1.14億。
據統計,南下資金已連續22日淨賣出騰訊,共計218.9477億港元;連續14日淨買入建設銀行,共計103.1683億港元;連續8日淨買入中芯國際,共計56.2551億港元。

北水關注個股
建設銀行:擬發行年內首期債券通綠色金融債,規模300億元
信達生物:公司宣佈,瑪仕度肽注射液(商品名:信爾美)獲得中國國家藥品監督管理局(NMPA)批準上市。這是全球首個且唯一上市的GCG/GLP-1雙受體激動減重降糖藥物,將與諾和諾德的司美格魯肽、禮來的替爾泊肽直接競爭。
騰訊控股:公司公告,於6月30日,公司回購98.9萬股股份,每股回購價格爲503港元-510港元,耗資約5億港元。
小米集團-W:雷軍發文稱,小米YU7發佈以來,媒體和用戶朋友們在試駕後給出了很多好評,鎖單也遠超預期,將於7月2日晚8點做一場直播,集中回答大家關心的一些問題。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.